A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial

Statistics in Medicine

Volumn 29, Issue 20, 2010, Pages 2107-2116

  Matsuyama, Yutaka ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

G estimation; Intent to treat; Non compliance; Non inferiority trials; Per protocol; Randomization based analysis

Indexed keywords

ARTICLE; G ESTIMATION METHOD; INTENT TO TREAT ANALYSIS; PER PROTOCOL ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

BIAS (EPIDEMIOLOGY); BIOSTATISTICS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HUMANS; MODELS, STATISTICAL; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS;

EID: 77956305085     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3987     Document Type: Article

References (35)

1. Temple R, Ellenberg SS. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000; 133:455-463.
2. Ellenberg SS, Temple R. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Annals of Internal Medicine 2000; 133:464-470.
3. D'Agostino RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22:169-186. DOI: 10.1002/sim.1425.
4. Rothmann M, Li N, Chen G, Chi GTH, Temple R, Tsou HH. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 2003; 22:239-264. DOI: 10.1002/sim.1400. (Pubitemid 36163584)
5. Hung HMJ, Wang SJ, O'Neill RT. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials. Biometrical Journal 2005; 47:28-36. DOI: 10.1002/bimj.200410084.
6. Fleming TR. Current issues in non-inferiority trials. Statistics in Medicine 2008; 27:317-332. DOI: 10.1002/sim.2855.
7. Ebbutt AF, Frith L. Practical issues in equivalence trials. Statistics in Medicine 1998; 17:1691-1701.
8. Jones B, Jarvis P, Lewis J, Ebbutt A. Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 1996;313:36-39. (Pubitemid 26229889)
9. ICH Harmonised Tripartite Guideline. E9: statistical principles for clinical trials, 1998.
10. Sanchez MH, Chen X. Choosing the analysis population in non-inferiority studies: per protocol or intent-to-treat. Statistics in Medicine 2006; 25:1169-1181. DOI: 10.1002/sim.2244.
11. Committee on Proprietary Medical Products Points-to-Consider. Points to consider on switching between superiority and non-inferiority. CPMP, 2000.
12. Rohmel J. Therapeutic equivalence investigations: statistical considerations. Statistics in Medicine 1998; 17:1703-1714. (Pubitemid 28409926)
13. Hauck WW, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Information Journal 1999; 33:109-118. (Pubitemid 29104657)
14. Garrett AD. Therapeutic equivalence: fallacies and falsification. Statistics in Medicine 2003; 22:741-762. DOI: 10.1002/sim.1360.
15. Sheng D, Kim MY. The effects of non-compliance on intent-to-treat analysis of equivalence trials. Statistics in Medicine 2006; 25:1183-1199. DOI: 10.1002/sim.2230.
16. Robins JM. Correcting for non-compliance in equivalence trials. Statistics in Medicine 1998; 17:269-302.
17. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Communications in Statistics 1991; 20:2609-2631.
18. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Controlled Clinical Trials 1993; 14:79-97.
19. Rubin DB. Bayesian inference for causal effects: the role of randomization. Annals of Statistics 1978; 6:34-58.
20. Robins JM. Causal inference from complex longitudinal data. In Latent Modelling with Applications to Causality, Berkane M (ed.). Springer: New York, 1997; 69-117.
21. VanderWeele TJ. Concerning the consistency assumption in causal inference. Epidemiology 2009; 20:880-883. DOI: 10.1097/EDE.0b013e3181bd5638.
22. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall: London, 1984.
23. Hernan MA, Cole SR, Margolick J, Cohen M, Robins JM. Structural accelerated failure time models for survival analysis in studies with time-varying treatments. Pharmacoepidemiology and Drug Safety 2005; 14:477-491. DOI: 10.1002/pds.1064. (Pubitemid 40990743)
24. Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and g-estimation. Clinical Trials 2008; 5:5-13.
25. Cheng SC, Wei LJ, Ying Z. Analysis of transformation models with censored data. Biometrika 1995; 82:835-845.
26. Korhonen PAK, Laird NM, Palmgren J. Correcting for non-compliance in randomized trials: an application to the ATBC study. Statistics in Medicine 1999; 18:2879-2897. (Pubitemid 29500029)
27. Gail MH, Wieand S, Piantadosi S. Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. Biometrika 1984; 71:431-444.
28. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemporary Clinical Trials 2005; 26:300-310. DOI: 10.1016/j.cct.2005.01.009. (Pubitemid 40725994)
29. Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high-versus low-dose AZT treatment arms in an AIDS randomized trial. Journal of the American Statistical Association 1994; 89:737-749.
30. White IR, Goetghebeur EJT. Clinical trials comparing two treatment policies: which aspects of the treatment policies make a difference? Statistics in Medicine 1998; 17:319-339.
31. Robins JM. Information recovery and bias adjustment in proportional hazards regression analysis of randomized trials using surrogate makers. American Statistical Association Proceedings of the Biopharmaceutical Section, Alexandria, VA, 1993; 24-33.
32. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. Journal of the American Statistical Association 1995; 90:106-121.
33. Robins JM, Finkelstein DH. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56:779-788.
34. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Statistics in Medicine 2009; 28:1725-1738. DOI: 10.1002/sim.3585.
35. Robins JM. Correcting for non-compliance in randomized trials using structural nested mean models. Communications in Statistics 1994; 23:2379-2412.